Navigation

Published technology appraisals

This table lists published NICE technology appraisals. The list can be sorted by title (alphabetically), issue date and review date. You can also:

  • click the appraisal title for full details
  • click a column heading to sort the list by that column

Please note that the 'review date' is not the date when a review of it the appraisal starts, but the date NICE consults on a proposal for reviewing it. There is no guarantee that at the review date, a review will be undertaken. Appraisals which have been considered for review and where the decision has been not to carry out a review at this time are listed in static technology appraisals.

More information on the published appraisals list.

For technology appraisal guidance organised by category, use Find guidance in the main header area above.

Searching for specific technology appraisal guidance?

Published appraisals

Results 1-20 of 311

Ref Title Date Issued Review
TA309 Lung cancer (non small cell, non squamous) - pemetrexed (TA309) Apr 2014 Apr 2017
TA310 Lung cancer (non small cell, EGFR mutation positive) - afatinib (TA310) Apr 2014 Apr 2017
TA311 Multiple myeloma - bortezomib (induction therapy) (TA311) Apr 2014 Apr 2017
TA308 Vasculitis (anti-neutrophil cytoplasmic antibody-associated) - rituximab (with glucocorticoids) (TA308) Mar 2014 Mar 2017
TA307 Colorectal cancer (metastatic) - aflibercept (TA307) Mar 2014 Aug 2016
TA304 Arthritis of the hip (end stage) - hip replacement (total) and resurfacing arthroplasty (Rev TA2, TA44) (TA304) Feb 2014 Feb 2017
TA306 Lymphoma (non Hodgkin's, relapsed, refractory) - pixantrone monotherapy (TA306) Feb 2014 Nov 2016
TA305 Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (TA305) Feb 2014 Feb 2017
TA303 Multiple sclerosis (relapsing) - teriflunomide (TA303) Jan 2014 TBC
TA300 Hepatitis C (children and young people) - peginterferon alfa and ribavirin (TA300) Nov 2013 Sep 2016
TA301 Diabetic macular oedema - fluocinolone acetonide intravitreal implant (rapid review of TA271) (TA301) Nov 2013 Nov 2016
TA302 Juvenile idiopathic arthritis (systemic) - canakinumab (terminated appraisal) (TA302) Nov 2013 TBC
TA299 Leukaemia (chronic myeloid) - bosutinib (TA299) Nov 2013 Jun 2016
TA298 Choroidal neovascularisation (pathological myopia) - ranibizumab (TA298) Nov 2013 Mar 2016
TA297 Vitreomacular traction - ocriplasmin (TA297) Oct 2013 Oct 2016
TA296 Lung cancer (non-small-cell, anaplastic lymphoma kinase fusion gene, previously treated) - crizotinib (TA296) Sep 2013 May 2016
TA295 Breast cancer (HER2 negative, oestrogen receptor positive, locally advanced or metastatic) - everolimus (with an aromatase inhibitor) (TA295) Aug 2013 Jun 2016
TA292 Bipolar disorder (adolescents) - aripiprazole (TA292) Jul 2013 Jul 2017
TA294 Macular degeneration (wet age-related) - aflibercept (TA294) Jul 2013 Feb 2014
TA293 Thrombocytopenic purpura - eltrombopag (TA293) Jul 2013 Mar 2014

This page was last updated: 23 April 2014

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.